Aside from a small number of companies the FDA has permitted to pursue the development of psilocybin therapies (e.g., Compass), the majority of psychedelic mushroom sales in the U.S. currently violate both state and federal...more
12/3/2021
/ Adverse Events ,
Advertising ,
Biologics ,
Controlled Substances Act ,
Dietary Supplements ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Food and Drug Administration (FDA) ,
GRAS ,
Labeling ,
Life Sciences ,
Marijuana ,
Popular ,
Reporting Requirements